Who are Sunrabin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inqovi, CEDAZURIDINE, Dacogen, Arranon, Vidaza, AZACITIDINE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enocitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sunrabin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sunrabin (ENOCITABINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside Metabolic Inhibitor. Area: Metabolic.

phase 2 Nucleoside Metabolic Inhibitor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Sunrabin (ENOCITABINE). Sunrabin works by incorporating itself into viral DNA, thereby disrupting its replication and transcription.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sunrabin TARGET	ENOCITABINE		phase 2	Nucleoside Metabolic Inhibitor
Inqovi	Inqovi	Otsuka	marketed	Nucleoside Metabolic Inhibitor [EPC]	Cytidine deaminase	2020-01-01
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01
Arranon	NELARABINE	Novartis	marketed	Nucleoside Metabolic Inhibitor [EPC]		2005-01-01
Vidaza	azacitidine	Bristol-Myers Squibb	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2004-01-01
AZACITIDINE	AZACITIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]		2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-16 — Inqovi · 8618075 · US
2028-10-16 — Inqovi · 9567363 · US
2029-05-14 — Vidaza · 12053482 · Method of Use · US
2029-05-14 — Vidaza · 11571436 · Formulation · US
2030-06-03 — Vidaza · 8846628 · Formulation · US
2030-08-22 — Inqovi · 8268800 · US

Sponsor landscape (Nucleoside Metabolic Inhibitor class)

· 2 drugs in this class
Accord Hlthcare · 1 drug in this class
Nihon Schering K.K. · 1 drug in this class
Spectrum Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sunrabin — Competitive Intelligence Brief. https://druglandscape.com/ci/enocitabine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing